XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis
| Autor: | Zhifeng Lin, Yun Wu, Fan-zhen Lu, Xiao-yong Shen, Li-ting Zhao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Systematic Reviews Clinical Research Design Epidemiology medicine.medical_treatment Cancer Treatment lcsh:Medicine Biology Lung and Intrathoracic Tumors XRCC3 Diagnostic Medicine Carcinoma Non-Small-Cell Lung Internal medicine Genetics medicine Carcinoma Humans Allele lcsh:Science Alleles Platinum Clinical Genetics Chemotherapy Polymorphism Genetic Multidisciplinary lcsh:R Cancers and Neoplasms Publication bias Chemotherapy and Drug Treatment medicine.disease Non-Small Cell Lung Cancer DNA-Binding Proteins Treatment Outcome Systematic review Meta-analysis Genetic Polymorphism Medicine lcsh:Q Non small cell Meta-Analyses Population Genetics Research Article |
| Zdroj: | PLoS ONE, Vol 8, Iss 8, p e69553 (2013) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | INTRODUCTION: X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy. METHODS: A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy. Response to chemotherapy, overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS: A number of 11 eligible studies were identified according to the inclusion criteria. Carriers of the variant XRCC3 241Met allele were significantly associated with good response to platinum-based chemotherapy (ThrMet/MetMet vs. ThrThr: OR = 1.509, 95% CI: 1.099-2.072, Pheterogeneity = 0.618). The XRCC3 Thr241Met polymorphism was not associated with OS (MetMet vs. ThrThr, HR = 0.939, 95% CI:0.651-1.356, Pheterogeneity = 0.112) or PFS (MetMet vs. ThrThr, HR = 0.960, 95% CI: 0.539-1.710, Pheterogeneity = 0.198). Additionally, no evidence of publication bias was observed. CONCLUSIONS: This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|